What is Cellectar Biosciences Inc's earnings per share (EPS)?

Cellectar Biosciences Inc (CLRB) reported diluted earnings per share of -$8.35 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cellectar Biosciences Inc Financials

CLRB

FY2025 annual

Revenue Not reported for FY2025

Net Income -$21.8M +51.1% YoY

EPS (Diluted) -$8.35 YoY not available

Free Cash Flow -$23.1M +51.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

This page shows Cellectar Biosciences Inc (CLRB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLRB FY2025 2026-08-13

Repeated capital raises keep an asset-light research program running while operating cash use, not capex, drives the balance sheet.

FY2025 net loss fell sharply to -$21.8M from -$44.6M, but that accounting improvement did not create a self-funding model. Operating cash flow was still -$23.1M while capex was only $6K, which means the cash demand comes from running research and overhead, not from building hard assets.

The balance sheet looks healthier than FY2023—current ratio recovered from 0.4x to 3.0x and equity turned positive—but that repair reflects external funding rather than internally generated cash. FY2025 ended with $13.2M of cash against annual operating cash use of -$23.1M, so liquidity still depends on replenishment.

The spending mix also shifted: in FY2025, R&D and SG&A were nearly equal at $11.5M and $11.5M, unlike earlier years when research spending clearly led. That suggests the lower burn came from a broad reset in activity levels, not from scale benefits in an established operating base.

Financial Health Signals

Financial health score not available

Cellectar Biosciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Cellectar Biosciences Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Cellectar Biosciences Inc reported a net loss of $21.8M while operations used $23.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$22.8M

YoY+55.8%

Cellectar Biosciences Inc's EBITDA was -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.8% from the prior year.

Net Income

-$21.8M

YoY+51.1%

Cellectar Biosciences Inc reported -$21.8M in net income in fiscal year 2025. This represents an increase of 51.1% from the prior year.

EPS (Diluted)

-$8.35

Cellectar Biosciences Inc earned -$8.35 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$23.1M

YoY+51.5%

Cellectar Biosciences Inc recorded an outflow of $23.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 51.5% from the prior year.

Cash & Debt

$13.2M

YoY-43.3%

5Y CAGR-25.4%

10Y CAGR+12.9%

Cellectar Biosciences Inc held $13.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Cellectar Biosciences Inc had 4M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-255.3%

YoY+56.6pp

Cellectar Biosciences Inc's ROE was -255.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 56.6 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$11.5M

YoY-56.0%

5Y CAGR+2.5%

10Y CAGR+8.3%

Cellectar Biosciences Inc invested $11.5M in research and development in fiscal year 2025. This represents a decrease of 56.0% from the prior year.

Capital Expenditures

$6K

YoY-94.4%

5Y CAGR-37.6%

10Y CAGR-20.5%

Cellectar Biosciences Inc invested $6K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 94.4% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

CLRB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CLRB quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
R&D Expenses	N/A	$11.5M-56.0%	$26.1M-4.1%	$27.3M+49.3%	$18.3M+3.9%	$17.6M+73.4%	$10.1M+12.7%	$9.0M+31.6%	$6.8M-27.8%	$9.5M+99.3%	$4.8M-7.9%	$5.2M-13.5%	$6.0M-13.1%	$6.9M+33.9%	$5.1M+42.3%	$3.6M
SG&A Expenses	N/A	$11.5M-55.2%	$25.6M+119.3%	$11.7M+10.9%	$10.5M+61.2%	$6.5M+27.1%	$5.1M-0.6%	$5.2M+7.5%	$4.8M+16.6%	$4.1M-12.0%	$4.7M+38.4%	$3.4M-8.3%	$3.7M-16.7%	$4.4M+22.4%	$3.6M+34.9%	$2.7M
Operating Income	N/A	-$23.0M+55.6%	-$51.8M-32.9%	-$39.0M-35.2%	-$28.8M-19.4%	-$24.1M-57.8%	-$15.3M-7.8%	-$14.2M-6.4%	-$13.3M+2.0%	-$13.6M-43.9%	-$9.4M-7.9%	-$8.8M+11.5%	-$9.9M+20.2%	-$12.4M-41.7%	-$8.8M-24.4%	-$7.0M
Income Tax	N/A	N/A	$66K+210.0%	-$60K0.0%	-$60K	N/A	N/A	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$1.1M
Net Income	N/A	-$21.8M+51.1%	-$44.6M-17.4%	-$38.0M-19.5%	-$31.8M-31.8%	-$24.1M-59.8%	-$15.1M-7.1%	-$14.1M-6.4%	-$13.2M+2.4%	-$13.6M-119.4%	-$6.2M-12.5%	-$5.5M+31.8%	-$8.1M+25.3%	-$10.8M-22.6%	-$8.8M-18.3%	-$7.4M
EPS (Diluted)	—	-$8.35	-$41.89	-$3.50	-$4.51	-$4.35-136.4%	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$4.6M+51.5%	$3.0M	N/A	$2.5M+5.6%	$2.4M-30.3%	$3.4M	N/A	$5.5M
SG&A Expenses	$2.6M-5.3%	$2.8M	N/A	$2.3M-36.2%	$3.6M+22.7%	$3.0M	N/A	$7.8M
Operating Income	-$7.2M-24.2%	-$5.8M	N/A	-$4.9M+19.7%	-$6.0M+5.7%	-$6.4M	N/A	-$13.3M
Net Income	-$6.9M-22.6%	-$5.7M	N/A	-$4.4M+18.4%	-$5.4M+17.5%	-$6.6M	N/A	-$14.7M
EPS (Diluted)	-$0.57	-$1.33-150.9%	-$0.53+62.4%	-$1.41	-$3.39	-$4.30-4200.0%	-$0.10+99.2%	-$12.13

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

CLRB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CLRB quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$15.0M-41.2%	$25.5M+111.0%	$12.1M-44.1%	$21.6M-42.0%	$37.2M-36.6%	$58.7M+378.8%	$12.3M-18.6%	$15.1M+17.0%	$12.9M-16.0%	$15.3M+101.7%	$7.6M-43.4%	$13.4M+96.9%	$6.8M-40.6%	$11.5M+8.7%	$10.6M
Current Assets	$14.0M-42.1%	$24.3M+132.0%	$10.5M-49.1%	$20.5M-43.9%	$36.6M-36.9%	$57.9M+408.9%	$11.4M-18.4%	$14.0M+33.2%	$10.5M-14.1%	$12.2M+191.7%	$4.2M-56.9%	$9.7M+250.4%	$2.8M-46.0%	$5.1M-11.8%	$5.8M
Cash & Equivalents	$13.2M-43.3%	$23.3M+143.5%	$9.6M-51.9%	$19.9M-44.4%	$35.7M-37.5%	$57.2M+438.5%	$10.6M-19.9%	$13.3M+32.5%	$10.0M-12.6%	$11.4M+192.5%	$3.9M-58.5%	$9.4M+289.6%	$2.4M-48.3%	$4.7M-15.0%	$5.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M0.0%	$1.7M
Total Liabilities	$5.1M-48.4%	$9.8M-62.1%	$25.9M+114.5%	$12.1M+190.0%	$4.2M+7.6%	$3.9M+21.1%	$3.2M+78.0%	$1.8M-15.3%	$2.1M+18.6%	$1.8M-70.0%	$5.9M-11.5%	$6.7M+31.4%	$5.1M+287.7%	$1.3M+22.0%	$1.1M
Current Liabilities	$4.7M-49.4%	$9.4M-63.0%	$25.4M+120.5%	$11.5M+188.2%	$4.0M+12.0%	$3.6M+28.6%	$2.8M+70.7%	$1.6M-23.3%	$2.1M+29.5%	$1.6M-71.4%	$5.7M-8.5%	$6.2M+37.8%	$4.5M+517.3%	$733K+45.5%	$504K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$330K-26.6%	$450K0.0%	$450K0.0%	$450K	N/A
Total Equity	$8.5M-40.3%	$14.3M+194.3%	-$15.2M-285.9%	$8.2M-71.9%	$29.1M-47.0%	$54.8M+504.8%	$9.1M-31.7%	$13.3M+23.3%	$10.8M-20.6%	$13.5M+720.7%	$1.6M-75.4%	$6.7M+294.1%	$1.7M-83.3%	$10.2M+7.1%	$9.5M
Retained Earnings	-$269.1M-8.8%	-$247.3M-22.0%	-$202.8M-26.7%	-$160.0M-6.0%	-$150.9M-19.0%	-$126.8M-13.5%	-$111.7M-14.4%	-$97.6M-15.7%	-$84.3M-19.2%	-$70.8M-9.6%	-$64.6M-9.3%	-$59.1M-15.8%	-$51.1M	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$36.6M+229.5%	$11.1M-25.8%	$15.0M+2.4%	$14.6M+6.8%	$13.7M-14.6%	$16.0M-37.0%	$25.5M-31.7%	$37.3M
Current Assets	$34.9M+276.4%	$9.3M-34.0%	$14.0M+3.1%	$13.6M+8.0%	$12.6M-15.3%	$14.9M-38.6%	$24.3M-32.4%	$35.9M
Cash & Equivalents	$34.0M+307.3%	$8.3M-36.7%	$13.2M+5.1%	$12.6M+13.7%	$11.0M-20.6%	$13.9M-40.3%	$23.3M-32.0%	$34.3M
Total Liabilities	$6.8M+5.7%	$6.4M+26.6%	$5.1M-3.6%	$5.2M-15.7%	$6.2M-2.8%	$6.4M-34.6%	$9.8M-52.8%	$20.7M
Current Liabilities	$5.2M+7.5%	$4.9M+2.6%	$4.7M-3.3%	$4.9M-16.3%	$5.9M-2.6%	$6.0M-35.9%	$9.4M-53.8%	$20.3M
Total Equity	$29.9M+795.7%	$3.3M-60.9%	$8.5M+6.8%	$8.0M+31.4%	$6.1M-26.3%	$8.3M-42.3%	$14.3M-5.7%	$15.2M
Retained Earnings	-$281.7M-2.5%	-$274.8M-2.1%	-$269.1M-2.0%	-$263.8M-1.7%	-$259.4M-2.1%	-$253.9M-2.7%	-$247.3M-1.0%	-$245.0M

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CLRB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CLRB quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$19.5M	-$23.1M+51.4%	-$47.6M-47.0%	-$32.4M-28.4%	-$25.2M-11.8%	-$22.6M-62.0%	-$13.9M-19.1%	-$11.7M-2.2%	-$11.4M-3.8%	-$11.0M-33.1%	-$8.3M-0.8%	-$8.2M+7.1%	-$8.8M+3.4%	-$9.2M-39.0%	-$6.6M-10.3%	-$6.0M
Capital Expenditures	N/A	$6K-94.4%	$104K-87.9%	$864K+282.4%	$226K+59.9%	$141K+126.7%	$62K+154.1%	$25K-93.6%	$385K+11.0%	$347K+379.9%	$72K+23.6%	$58K+97.7%	$30K-80.0%	$148K+51.3%	$98K-17.5%	$118K
Free Cash Flow	N/A	-$23.1M+51.5%	-$47.7M-43.5%	-$33.2M-30.6%	-$25.4M-12.1%	-$22.7M-62.3%	-$14.0M-19.4%	-$11.7M+0.9%	-$11.8M-4.0%	-$11.4M-36.1%	-$8.4M-1.0%	-$8.3M+6.7%	-$8.9M+4.6%	-$9.3M-39.2%	-$6.7M-9.8%	-$6.1M
Investing Cash Flow	N/A	-$6K+94.4%	-$104K+87.9%	-$864K-282.4%	-$226K-59.9%	-$141K-126.7%	-$62K-154.1%	-$25K+92.6%	-$330K+4.8%	-$347K-379.9%	-$72K	N/A	N/A	N/A	-$2.1M-263.0%	$1.3M
Financing Cash Flow	N/A	$13.0M-78.8%	$61.4M+167.7%	$22.9M+138.7%	$9.6M+669.6%	$1.2M-97.9%	$60.5M+571.1%	$9.0M-39.9%	$15.0M+51.3%	$9.9M-37.7%	$15.9M	N/A	N/A	N/A	$7.9M-17.5%	$9.5M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.0M-24.0%	-$4.8M-11.5%	-$4.3M-1.6%	-$4.3M+16.4%	-$5.1M+45.5%	-$9.4M+14.0%	-$10.9M-19.1%	-$9.2M
Capital Expenditures	$0-100.0%	$3K	N/A	N/A	N/A	N/A	$61K	$0
Free Cash Flow	-$6.0M-23.9%	-$4.8M	N/A	N/A	N/A	N/A	-$11.0M-19.7%	-$9.2M
Investing Cash Flow	$0+100.0%	-$3K	N/A	N/A	N/A	N/A	-$61K	$0
Financing Cash Flow	N/A	N/A	$5.0M-13.8%	$5.8M	N/A	N/A	$0-100.0%	$17.6M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CLRB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CLRB quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Return on Equity	-255.3%+56.6pp	-311.9%	N/A	-389.9%-306.9pp	-83.0%-55.5pp	-27.6%+128.0pp	-155.6%-55.7pp	-99.8%+26.3pp	-126.1%-80.5pp	-45.6%+287.4pp	-333.1%-212.9pp	-120.2%+514.2pp	-634.4%-547.8pp	-86.6%-8.2pp	-78.4%
Return on Assets	-145.5%+29.5pp	-175.0%+139.5pp	-314.6%-167.3pp	-147.3%-82.4pp	-64.8%-39.1pp	-25.7%+89.3pp	-115.0%-27.1pp	-87.9%+17.4pp	-105.4%-65.0pp	-40.3%+32.0pp	-72.3%-12.3pp	-60.0%+98.2pp	-158.2%-81.6pp	-76.6%-6.3pp	-70.4%
Current Ratio	2.96+0.4x	2.58+2.2x	0.41-1.4x	1.78-7.4x	9.16-7.1x	16.26+12.2x	4.11-4.5x	8.60+3.6x	4.95-2.5x	7.47+6.7x	0.73-0.8x	1.56+0.9x	0.61-6.4x	7.00-4.5x	11.55
Debt-to-Equity	0.59-0.1x	0.69	N/A	1.48+1.3x	0.14+0.1x	0.07-0.3x	0.35+0.2x	0.14-0.1x	0.20+0.1x	0.13-0.1x	0.20+0.1x	0.07-0.2x	0.26+0.2x	0.04-0.1x	0.11

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-23.2%+146.3pp	-169.5%	N/A	-55.6%+34.0pp	-89.5%-9.5pp	-80.0%	N/A	-96.7%
Return on Assets	-18.9%+31.9pp	-50.8%	N/A	-30.4%+9.4pp	-39.8%+1.4pp	-41.2%	N/A	-39.3%
Current Ratio	6.66+4.8x	1.90-1.1x	2.96+0.2x	2.77+0.6x	2.15-0.3x	2.47-0.1x	2.58+0.8x	1.77
Debt-to-Equity	0.23-1.7x	1.92+1.3x	0.59-0.1x	0.66-0.4x	1.02+0.2x	0.78+0.1x	0.69-0.7x	1.37

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Edesa Biotech Inc EDSA

$42.9M

Tharimmune Inc THAR

$187.4M

Lisata Therapeutics Inc LSTA

$15.7M

Pulmatrix PULM

$5.8M

Synlogic SYBX

$6.6M

Where Cellectar Biosciences Inc Ranks

Frequently Asked Questions

Is Cellectar Biosciences Inc profitable?

No, Cellectar Biosciences Inc (CLRB) reported a net income of -$21.8M in fiscal year 2025.

What is Cellectar Biosciences Inc's EBITDA?

Cellectar Biosciences Inc (CLRB) had EBITDA of -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cellectar Biosciences Inc's return on equity (ROE)?

Cellectar Biosciences Inc (CLRB) has a return on equity of -255.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cellectar Biosciences Inc's free cash flow?

Cellectar Biosciences Inc (CLRB) recorded an outflow of $23.1M in free cash flow during fiscal year 2025. This represents a 51.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cellectar Biosciences Inc's operating cash flow?

Cellectar Biosciences Inc (CLRB) recorded an outflow of $23.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Cellectar Biosciences Inc's total assets?

Cellectar Biosciences Inc (CLRB) had $15.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cellectar Biosciences Inc's capital expenditures?

Cellectar Biosciences Inc (CLRB) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cellectar Biosciences Inc spend on research and development?

Cellectar Biosciences Inc (CLRB) invested $11.5M in research and development during fiscal year 2025.

How many shares does Cellectar Biosciences Inc have outstanding?

Cellectar Biosciences Inc (CLRB) had 4M shares outstanding as of fiscal year 2025.

What is Cellectar Biosciences Inc's current ratio?

Cellectar Biosciences Inc (CLRB) had a current ratio of 2.96 as of fiscal year 2025, which is generally considered healthy.

What is Cellectar Biosciences Inc's debt-to-equity ratio?

Cellectar Biosciences Inc (CLRB) had a debt-to-equity ratio of 0.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cellectar Biosciences Inc's return on assets (ROA)?

Cellectar Biosciences Inc (CLRB) had a return on assets of -145.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Cellectar Biosciences Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Cellectar Biosciences Inc (CLRB) held $13.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Cellectar Biosciences Inc's Piotroski F-Score?

Cellectar Biosciences Inc (CLRB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cellectar Biosciences Inc's earnings high quality?

Cellectar Biosciences Inc (CLRB) reported a net loss of $21.8M while operations used $23.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.